Novaliq’s innovative EyeSol® drug delivery technology is based on novel and exclusive water-free excipients which have been established and validated as key ingredients for innovative ophthalmic products:
- the technology platform is disruptive and IP protected;
- the pipeline is rich with first-in-class candidates for dry eye, glaucoma and retinal diseases;
- the technology is clinically proven to be safe and effective;
- Novaliq has generated a broad range of clinical and pre-clinical data to confirm safety, tolerability, efficacy and comfort.
How does the EyeSol® drug delivery technology work?
Our EyeSol® technology enhances traditionally water-insoluble or unstable drugs resulting in:
- eye drops with better and higher solubility, stability, bioavailability, safety and comfort;
- overcoming the limitations of water-based drug instabilities;
- formulations that are always water-free and therefore preservative-free;
- better penetration in tissues;
- better drug delivery, efficacy and longer retention;
- multi-dose presentations;
- small drop size, excellent spreading.
Our fast and proven drug development process increases success and time to market.
What are the benefits of the technology?
Novaliq’s disruptive, IP protected EyeSol® technology platform enables our partners to
- get access to innovative products to protect, treat and manage ocular diseases for increased effectiveness and better stability;
- formulate and stabilize a wide range of APIs, including macromolecules and proteins;
- enable poorly soluble APIs by utilizing a new kind of drug delivery.